G. Balaratnam

发表

Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor

V. Gordeuk, Winfred C. Wang, Y. Yaron, 2017 .

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment

R. Preston, T. Marbury, Michelle L. Green, 2020, Journal of clinical pharmacology.

A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.

K. Swiderek, J. Mitcham, A. Bonavia, 2015, The Journal of infectious diseases.

Correction: Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans

J. Oxford, Rob Lambkin-Williams, A. Mann, 2015, Clinical and Vaccine Immunology.

Running Title: Live virus challenge trial of T cell influenza vaccine 4

J. Oxford, Rob Lambkin-Williams, A. Mann, 2015 .

Comparing Influenza and Rsv Viral and Disease Dynamics in Experimentally Infected Adults Predicts Clinical Effectiveness of Rsv Antivirals

J. Oxford, Rob Lambkin-Williams, A. Mann, 2013, Antiviral therapy.

LONG-TERM SAFETY OF MAVACAMTEN IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: INTERIM RESULTS OF THE MAVA-LONG TERM EXTENSION (LTE) STUDY

M. Wheeler, T. Abraham, D. Zwas, 2021 .

Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study

H. Fennema, J. Symons, P. van Remoortere, 2018, The Journal of infectious diseases.

LONG-TERM SAFETY AND EFFICACY OF MAVACAMTEN IN PATIENTS (PTS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM): UPDATED RESULTS FROM THE PIONEER-OLE STUDY

S. Lester, A. Sehnert, G. Balaratnam, 2023, Journal of the American College of Cardiology.

Abstract 13962: Precision Pharmacological Treatment for Obstructive Hypertrophic Cardiomyopathy With Mavacamten: One-Year Results From PIONEER-OLE

D. Jacoby, S. Heitner, S. Lester, 2019 .

228Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study

D. Jacoby, S. Heitner, S. Lester, 2019, European Heart Journal.